United Kingdom

SanBio Co Ltd (4592.T)

4592.T on Tokyo Stock Exchange

24 May 2019
Change (% chg)

¥80 (+2.14%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


SanBio Company Limited is a Japan-based company primarily engaged in the research and development of regenerative cells drugs. The Company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular... (more)


Beta: 0.67
Market Cap(Mil.): ¥185,504.91
Shares Outstanding(Mil.): 49.73
Dividend: --
Yield (%): --


  4592.T Industry Sector
P/E (TTM): -- 94.22 35.45
EPS (TTM): -60.25 -- --
ROI: -36.52 7.58 11.75
ROE: -59.83 8.15 16.50

Nikkei ends flat despite strong chip makers

TOKYO, March 22 Japan's Nikkei ended little changed on Friday as chip-related stocks offset weakness in financial stocks and drugmakers, which tumbled after Eisai said it will end its Alzheimer drug trials.

22 Mar 2019

Nikkei falls as financials drag; Eisai indicated to dive

TOKYO, March 22 Japan's Nikkei fell in choppy trade on Friday as financial stocks languished, reflecting more cautious U.S. monetary policy, while the drug sector tumbled after Eisai and Biogen said they will end their Alzheimer's drug trials.

22 Mar 2019

SanBio's crash causes margin calls, drags down Japan's start-up market

TOKYO A crash by a Tokyo biopharmaceutical firm's shares on Wednesday ended a month-long rally in Japan's start-up market that was fueled by retail investors feeling small-cap stocks could rise despite global economic risks.

30 Jan 2019

SanBio's crash causes margin calls, drags down Japan's start-up market

* Mothers market, +18 pct in Jan through Tuesday, tumbles 8.1 pct

30 Jan 2019

Earnings vs. Estimates